UK biotechnology company SolasCure has commenced the randomised, controlled CLEANVLU2 Phase II trial of Aurase Wound Gel for ...

FibroBiologics and Charles River have announced the completion of FibroBiologics’ master cell bank for a product that will be evaluated for the treatment of diabetic foot ulcers and other chronic ...

Wounds are more than just skin deep. They can affect every aspect of a person’s life, from mobility and independence to overall health and well-being. Whether you are dealing with ...

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of a new Phase II clinical trial, CLEANVLU2.

Slow wound healing and related complications are common in diabetes. Compromised blood circulation and nerve damage are among the causes of delayed recovery in people with diabetes. Foot ulcers ...

SolasCure has initiated a new Phase II clinical trial, CLEANVLU2, to further the development of its investigational product, ...